AWD 140-190: A potent anticonvulsant in the amygdala-kindling model of partial epilepsy

Epilepsia

Volumn 42, Issue 5, 2001, Pages 590-599

  Tober, Christine ^a,c   Löscher, Wolfgang ^b   Hönack, Dagmar ^b   Bartsch, Reni ^a  

^a ASTA MEDICA AG   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

Amygdala kindling; Anticonvulsant drug; AWD 140 190; Epilepsy; Kindling development

Indexed keywords

4 (4 BROMOPHENYL) 3 MORPHOLINO 1H PYRROLE 2 CARBOXYLIC ACID METHYL ESTER; AWD 140 190; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

AFTERDISCHARGE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; EPILEPSY; EPILEPTOGENESIS; FEMALE; FOCAL EPILEPSY; KINDLING; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ADMINISTRATION, ORAL; AMYGDALA; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; KINDLING, NEUROLOGIC; MORPHOLINES; PROLINE; RATS; RATS, WISTAR;

EID: 0035006899     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.19300.x     Document Type: Article

References (42)

1. Löscher W, Schmidt D. New drugs for the treatment of epilepsy. Curr Opin Invest Drugs 1993;2:1067-95.
2. Mattson RH. Introduction and symposium overview. Epilepsia 1996;37(suppl 6):S1-3.
3. Gram L. Antiepileptic drug monotherapy designs in clinical trials. Epilepsia 1997;38(suppl 5):S14-6.
4. Gasior M, Carter R, Witkin JM. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. TiPS 1999;20:107-12.
5. Rostock A, Tober C, Rundfeldt C, et al. AWD 140-190: a new anticonvulsant with a very good margin of safety. Epilepsy Res 1997;28:17-28.
6. Rostock A, Tober C, Bartsch R, et al. Anticonvulsive profile of AWD 140-190, a derivative of a series of 3-aminopyrroles. Epilepsia 1994;35(suppl 7):76.
7. Rostock A, Rundfeldt C, Tober C, et al. AWD 140-190: a new anticonvulsant with sodium channel blocking properties. Soc Neurosci Abstr 1995;21:203.
8. Rostock A, Tober C, Rundfeldt C, et al. AWD 140-190 (4-(p-bromophenyl)-3-morpholino-pyrrole-2-carboxylic acid methyl ester): a new anticonvulsant with a very good margin of safety. Naunyn Schmiedebergs Arch Pharmacol 1995;(suppl 351):R159.
9. Rostock A, Tober C, Rundfeldt C, et al. High brain and plasma levels of AWD 140-190 in vivo are consistent with anticonvulsant activity and with use dependent sodium channel blockade. Epilepsia 1996;37(suppl 5):63.
10. Rostock A, Tober C, Seidel B, et al. Anticonvulsant activity and plasma concentration of AWD 140-190 in rats. Epilepsia 1995;36 (suppl 4):50.
11. Rundfeldt C. The novel anticonvulsant AWD 140-190 acts as a highly use-dependent sodium channel blocker in neuronal cell preparation. Epilepsy Res 1999;34:57-64.
12. Armand V, Heinemann U, Dost R, et al. AWD 140-190 exerts anticonvulsant activity in hippocampal slice preparations. Epilepsia 1996;37(suppl 4):52-3.
13. Armand V, Rundfeldt C, Heinemann U. Effects of AWD 140-190 on stimulus-induced field potentials and on different patterns of epileptiform activity induced by low calcium or low magnesium in rat entorhinal cortex hippocampal slices. Epilepsy Res 1997;29: 59-69.
14. Löscher W, Cramer S, Ebert U. Selection of phenytoin responders and nonresponders in male and female amygdala-kindled Spraque-Dawley rats. Epilepsia 1998;39:1138-47.
15. Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variations? Epilepsy Res 1994;17:95-134.
16. Racine RJ, Steingart M, McIntyre DC. Development of kindling-prone and kindling-resistant rats: selective breeding and electro-physiological studies. Epilepsy Res 1999;35:183-95.
17. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:145-81.
18. Wada Y, Shiraishi J, Nakamura M, et al. Biphasic action of the histamine precursor L-histidine in the rat kindling model of epilepsy. Neurosci Lett 1996;204:205-8.
19. 1A receptors. J Pharmacol Exp Ther 1991;257:1146-53.
20. Hönack D, Löscher W. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 1995;36: 763-71.
21. Shinnar S, Berg AT: Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Epilepsia 1996;37:701-8.
22. Pitkänen A, Halonen T. Prevention of epilepsy [Letter]. Trends Pharmacol Sci 1998;19:253-5.
23. McNamara JO, Bonhaus DW, Shin C. The kindling model of epilepsy. In: Schwartzkroin PA, ed. Epilepsy: models, mechanisms and concepts. Cambridge: University Press, 1993:27-47.
24. Silver JM, Shin C, McNamara JO. Antiepileplogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 1991;29:356-63.
25. Kulkarni SK, George B. Kindling model of epilepsy. Methods Fund Exp Clin Pharmacol 1994;16:735-45.
26. Tober C, Stark B, Bartsch R, et al. Effects of AWD 140-190 on the kindling development in the amygdala kindling model in rats. Epilepsia 1996;37(suppl 4):161-2.
27. Tober C, Rostock A, Rundfeldt C, et al. D-23129: a potent anti-convulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9.
28. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
29. Racine RJ. Modification of seizure activity by electrical stimulation: 1. After-discharge threshold. Electroencephalogr Clin Neurophysiol 1972;32:269-79.
30. Löscher W, Hönack D. Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy. J Pharmacol Exp Ther 1995;274:307-14.
31. Hönack D, Löscher W. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 1995;36: 763-71.
32. Rundfeldt C, Hönack D, Löscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 1990;29:845-51.
33. Ebert U, Maier S, Löscher W. Phenytoin does not prevent the spread of epileptic activity in the amygdala-kindling model of the rat. Naunyn Schmiedebergs Arch Pharmacol 1996;353(suppl): R98.
34. Ebert U, Cramer S, Löscher W. Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn Schmiedebergs Arch Pharmacol 1997;356:341-7.
35. Albertson TE, Joy RM, Stark LG. Carbamazepine: a pharmacological study in the kindling model of epilepsy. Neuropharmacology 1984;23:1117-23.
36. Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy: comparison with MK 801 and carbamazepine. J Pharmacol Exp Ther 1991;256:432-40.
37. Löscher W, Rundfeldt C, Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res 1993;15:207-19.
38. Tober C, Rostock A, Bartsch R. Antiepileptogenic effect of D-23129 (retigabine) in the amygdala kindling model of epilepsy. Epilepsia 1997;38(suppl 8):113.
39. Racine RJ, Livingston K, Joaquin A. Effects of procaine hydrochloride, diazepam and diphenylhydantoin on seizure development in cortical and subcortical structures in rats. Electroencephalogr Clin Neurophysiol 1975;38:355-65.
40. Schmutz M, Klebs K, Baltzer V. Inhibition or enhancement of kindling evolution by antiepileptics. J Neural Transm 1988;72: 245-57.
41. Shin C, Legg S, McNamara JO. Systemic γ-vinyl GABA retards kindling development and suppresses kindled seizures. Soc Neurosci Abst 1984;10:343.
42. Shin C, Legg S, McNamara JO. Systemic γ-vinyl GABA retards kindling development and suppresses kindled seizures. Soc Neurosci Abst 1984;10:343.